Key statistics
As of last trade Immunitybio Inc (26CA:FRA) traded at 5.60, -17.16% below its 52-week high of 6.76, set on Jan 22, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.48 |
|---|---|
| High | 5.60 |
| Low | 5.48 |
| Bid | 5.50 |
| Offer | 5.59 |
| Previous close | 5.49 |
| Average volume | 23.20k |
|---|---|
| Shares outstanding | 984.97m |
| Free float | 330.88m |
| P/E (TTM) | -- |
| Market cap | 6.46bn USD |
| EPS (TTM) | -0.4079 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 08:14 GMT.
More ▼
Press releases
- ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
- ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
- ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
- ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
- ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
- ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
- Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
- Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
- ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
- NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security
More ▼
